News

Month Year

Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)

May 16, 2022
Aruvant to Participate in Multiple Conferences This Spring

Apr 19, 2022
Aruvant to Participate in Multiple Gene Therapy Conferences in March

Mar 3, 2022
Aruvant to Participate in the 2022 BIO CEO & Investor Gene Therapy Panel on February 16, 2022

Feb 7, 2022
Aruvant to Participate in Advanced Therapies Week January 25 to 28

Jan 20, 2022
Aruvant Appoints Moya Daniels as Senior Vice President of Regulatory Affairs and Quality Assurance

Nov 15, 2021

Industry leader brings relevant cell and gene therapy experience
Aruvant Announces ARU-1801 Data to be Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

Nov 4, 2021

--Clinical data demonstrates ARU-1801 may be a safe and effective treatment for patients with severe sickle cell disease --
Aruvant Announces ARU-2801 Data Oral Presentation at Society for Endocrinology BES 2021 Conference

Oct 26, 2021

-- Data to be presented shows improved survival out to 18 months in hypophosphatasia mice --
Aruvant to Participate in 2021 Cell & Gene Meeting on the Mesa to be Held Online and in Person October 12 to 14, 2021

Oct 5, 2021

Company to sponsor SCDAA 49th Annual National Convention to be held October 12 to 16, 2021
Aruvant Announces ARU-2801 Data Presentations at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

Sep 20, 2021

-Data demonstrates promise for ARU-2801 as a potential one-time gene therapy treatment for hypophosphatasia-

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa